A liquid formulation comprising an acellular extract of placental tissue and a solvent that may prevent the onset or reduce the symptoms of an intestinal condition in a subject when a therapeutically effective amount of the liquid formulation is delivered to a gastric system of the subject.

A liquid formulation comprising an acellular extract of placental tissue and a solvent that may prevent the onset or reduce the symptoms of an intestinal condition in a subject when a therapeutically effective amount of the liquid formulation is delivered to a gastric system of the subject.

Disclosed is a method of obtaining a protein-associated nanostructured complex (MRB-CFI-1) by chemical synthesis and antitumor use. The main use is in treating cancer, both in animals and humans. The complex has singular antitumor activity, and can potentially be used as a substitute and/or act as an adjuvant for other commercial antineoplastic drugs.

The system and method for providing antimicrobial and/or antiviral characteristics to substrates via an additive process for providing safe handling and reduction of cross contaminations from person to person from handling, shipping, storage and use of papers, boxes, liners, hospital barriers, respirator filters and liners, hospital curtains, masks, draperies, bed liners, and the like.

The system and method for providing antimicrobial and/or antiviral characteristics to substrates via an additive process for providing safe handling and reduction of cross contaminations from person to person from handling, shipping, storage and use of papers, boxes, liners, hospital barriers, respirator filters and liners, hospital curtains, masks, draperies, bed liners, and the like.

Disclosed is a method of obtaining an inorganic nanostructured complex (CFI-1) by chemical synthesis and antitumor use. The main use is in treating cancer, both in animals and humans. The complex has singular antitumor activity, and can potentially be used as a substitute and/or act as an adjuvant for other commercial antineoplastic drugs.

Methods of treating baldness, fibrotic disease, cancer and other pathological conditions resulting from abnormal cell proliferation, cardiovascular disease, metabolic syndrome, central nervous system disorders, platelet aggregation, platelet adhesion, disease caused by or characterized by low nitric oxide levels, transplantation rejections, autoimmune diseases, inflammation, vascular diseases, restenosis, pain, fever, gastrointestinal disorders, respiratory disorders, and sexual dysfunctions are disclosed. The methods involve administering specific nitric oxide-releasing compounds.

Methods of treating baldness, fibrotic disease, cancer and other pathological conditions resulting from abnormal cell proliferation, cardiovascular disease, metabolic syndrome, central nervous system disorders, platelet aggregation, platelet adhesion, disease caused by or characterized by low nitric oxide levels, transplantation rejections, autoimmune diseases, inflammation, vascular diseases, restenosis, pain, fever, gastrointestinal disorders, respiratory disorders, and sexual dysfunctions are disclosed. The methods involve administering specific nitric oxide-releasing compounds.

Disclosed is use of a composition for preventing and/or eliminating platelet aggregation in an in vitro blood sample. The composition comprises at least one compound selected from the group consisting of formula, R1-NH—R2, and a salt thereof. Also disclosed is an agent, which comprises the compound for reducing platelet aggregation interference in an in vitro blood test, and a method for preventing and/or eliminating platelet aggregation in a sample in an in vitro blood test. The compound of the present invention exhibits a disaggregation effect in multiple types of platelet aggregation circumstances, and the platelet disaggregation takes effect within a short time without additional conditions such as temperature control with water bath, prolonged reaction time and the like, thereby eliminating platelet aggregation in a sample conveniently and thus accurate blood cell detection parameters can be obtained.

Disclosed is use of a composition for preventing and/or eliminating platelet aggregation in an in vitro blood sample. The composition comprises at least one compound selected from the group consisting of formula, R1-NH—R2, and a salt thereof. Also disclosed is an agent, which comprises the compound for reducing platelet aggregation interference in an in vitro blood test, and a method for preventing and/or eliminating platelet aggregation in a sample in an in vitro blood test. The compound of the present invention exhibits a disaggregation effect in multiple types of platelet aggregation circumstances, and the platelet disaggregation takes effect within a short time without additional conditions such as temperature control with water bath, prolonged reaction time and the like, thereby eliminating platelet aggregation in a sample conveniently and thus accurate blood cell detection parameters can be obtained.